Last reviewed · How we verify

CBLB612 — Competitive Intelligence Brief

CBLB612 (CBLB612) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gene therapy. Area: Respiratory.

phase 2 Gene therapy CFTR gene Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

CBLB612 (CBLB612) — BioLab 612 LLC. CBLB612 is a gene therapy that aims to treat certain conditions by delivering a healthy copy of the CFTR gene to cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CBLB612 TARGET CBLB612 BioLab 612 LLC phase 2 Gene therapy CFTR gene
Onasemnogene Abeparvovec-xioi Onasemnogene Abeparvovec-xioi Novartis Gene Therapies marketed Gene therapy SMN1 gene
p53 with chemotherapy p53 with chemotherapy Shenzhen SiBiono GeneTech Co.,Ltd marketed Gene therapy; recombinant adenovirus vector p53 (tumor suppressor protein)
p53 gene therapy p53 gene therapy Shenzhen SiBiono GeneTech Co.,Ltd marketed Gene therapy p53 (tumor suppressor protein)
Onasemnogene Abeparvovec-brve Onasemnogene Abeparvovec-brve Novartis Pharmaceuticals marketed Gene Therapy SMN1 gene
p53 gene with surgery p53 gene with surgery Shenzhen SiBiono GeneTech Co.,Ltd marketed Gene therapy (p53 tumor suppressor) p53 (tumor protein p53)
voretigene neparvovec-rzyl voretigene neparvovec-rzyl Spark Therapeutics, Inc. marketed Gene therapy RPE65 gene

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gene therapy class)

  1. Spark Therapeutics, Inc. · 4 drugs in this class
  2. MeiraGTx UK II Ltd · 3 drugs in this class
  3. Novartis Gene Therapies · 2 drugs in this class
  4. Kolon TissueGene, Inc. · 2 drugs in this class
  5. Krystal Biotech, Inc. · 2 drugs in this class
  6. Abeona Therapeutics, Inc · 2 drugs in this class
  7. Larimar Therapeutics, Inc. · 1 drug in this class
  8. 4D Molecular Therapeutics · 1 drug in this class
  9. Medeor Therapeutics, Inc. · 1 drug in this class
  10. MeiraGTx, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CBLB612 — Competitive Intelligence Brief. https://druglandscape.com/ci/cblb612. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: